AIMS/HYPOTHESIS: The aim of this study was to investigate whether dynamic strength training modifies the control of lipolysis, with particular attention paid to the involvement of the antilipolytic adrenergic alpha 2A receptor (ADRA2A) pathway. METHODS: Twelve obese men (age: 47.4+/-2.8 years; BMI: 32.7+/-0.9) were investigated during a 210-min euglycaemic-hyperinsulinaemic clamp conducted before and after 3 months of dynamic strength training. Before and during the third hour of the clamp, the lipolytic effect of a perfusion of isoproterenol or adrenaline (epinephrine) alone or associated with the ADRA2A antagonist phentolamine was evaluated using the microdialysis method of measuring extracellular glycerol concentration (EGC) in subcutaneous abdominal adipose tissue (SCAAT). In addition, biopsies of SCAAT were carried out before and after training to determine mRNA levels RESULTS: The training increased insulin sensitivity in adipose tissue. The decrease of EGC was more pronounced during the clamp conducted after the training period than during the clamp done in pre-training conditions. Before and after the training, catecholamines induced an increase in EGC, the increase being lower during the clamp on each occasion. The isoproterenol-induced increase in EGC was higher after the training. Adrenaline-induced lipolysis was potentiated by phentolamine after but not before the training. There were no training-induced changes in mRNA levels of key genes of the lipolytic pathway in SCAAT. CONCLUSIONS/INTERPRETATION: In obese subjects, dynamic strength training improves whole-body and adipose tissue insulin responsiveness. It increases responsiveness to the adrenergic beta receptor stimulation of lipolysis and to the antilipolytic action of catecholamines mediated by ADRA2As.

Franco Czech Laboratory for Clinical Research on Obesity French Institute of Health and Medical Research and 3rd Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

J Clin Invest. 1992 May;89(5):1610-7 PubMed

Int J Obes Relat Metab Disord. 1999 Apr;23(4):374-81 PubMed

Horm Metab Res. 1998 Nov;30(11):684-8 PubMed

Metabolism. 1995 Dec;44(12):1513-8 PubMed

Biochem Biophys Res Commun. 1986 Dec 30;141(3):1157-61 PubMed

J Clin Invest. 1993 May;91(5):1997-2003 PubMed

Metabolism. 2005 Jan;54(1):122-31 PubMed

J Biol Chem. 1988 Oct 25;263(30):15553-60 PubMed

Am J Physiol Regul Integr Comp Physiol. 2000 Aug;279(2):R499-504 PubMed

J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10 PubMed

Int J Obes Relat Metab Disord. 1996 Mar;20(3):220-6 PubMed

Am J Clin Nutr. 1992 Jan;55(1 Suppl):228S-236S PubMed

J Clin Endocrinol Metab. 2004 Mar;89(3):1325-31 PubMed

Obes Res. 2003 Feb;11(2):247-56 PubMed

Am J Physiol. 1979 Sep;237(3):E214-23 PubMed

Endocr Rev. 1995 Dec;16(6):716-38 PubMed

Diabetes. 2004 Aug;53(8):1966-71 PubMed

J Clin Endocrinol Metab. 2004 Jan;89(1):135-41 PubMed

Am J Physiol Endocrinol Metab. 2000 Aug;279(2):E376-85 PubMed

Int J Obes Relat Metab Disord. 1995 May;19(5):350-4 PubMed

Nutrition. 2004 Jul-Aug;20(7-8):716-27 PubMed

Anal Biochem. 1989 Jul;180(1):11-6 PubMed

Am J Physiol Endocrinol Metab. 2003 Sep;285(3):E599-607 PubMed